[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=0970276a4204a60c577af15c4cda2956558fdf7698d6611ff597195d66bc1122",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731516240,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
      "id": 131418668,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=0970276a4204a60c577af15c4cda2956558fdf7698d6611ff597195d66bc1122"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease",
    "summary": "After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent recently gained FDA approval for COPD, marking its sixth U.S. indication since its first use for atopic dermatitis seven years ago. This expansion positions Dupixent as the first targeted therapy for COPD, a significant leap in treating this progressive lung condition that impedes breathing",
    "url": "https://finnhub.io/api/news?id=297ad95489ffc5af5de314dece7d8a5f09437389bace842e21f6a7725a7d4a9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731513969,
      "headline": "Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease",
      "id": 131327723,
      "image": "https://media.zenfs.com/en/Benzinga/71aab9106c528f6182315e0241f5403e",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent recently gained FDA approval for COPD, marking its sixth U.S. indication since its first use for atopic dermatitis seven years ago. This expansion positions Dupixent as the first targeted therapy for COPD, a significant leap in treating this progressive lung condition that impedes breathing",
      "url": "https://finnhub.io/api/news?id=297ad95489ffc5af5de314dece7d8a5f09437389bace842e21f6a7725a7d4a9b"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH",
    "summary": "Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first-line follicular lymphoma showcase compelling monotherapy potential and progress in the confirmatory trial Additional oral presentations explore odronextamab in areas of high unmet need, including the primary analysis in diffuse large B-cell lymphoma progressing after CAR-T therapy and first results",
    "url": "https://finnhub.io/api/news?id=8fe730bd5c754a223af9d78ce8f45730cd64694846462a2c9f39dd628aa1aed8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731499200,
      "headline": "Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH",
      "id": 131322821,
      "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first-line follicular lymphoma showcase compelling monotherapy potential and progress in the confirmatory trial Additional oral presentations explore odronextamab in areas of high unmet need, including the primary analysis in diffuse large B-cell lymphoma progressing after CAR-T therapy and first results",
      "url": "https://finnhub.io/api/news?id=8fe730bd5c754a223af9d78ce8f45730cd64694846462a2c9f39dd628aa1aed8"
    }
  }
]